Is Marijuana Schedule III? What the 2026 Order Changed

On 2026-04-23 the Acting Attorney General signed a final order on the rescheduling of marijuana under the federal Controlled Substances Act, published in the Federal Register on 2026-04-28. That much is real. What almost every summary drops is the limit written into the order itself: it reaches two defined categories of marijuana, and anything that falls into neither of them sits today exactly where it sat in March — in Schedule I.

The distance between those two sentences is why a search on this question returns confident answers that contradict each other. This page sets out what the April order covers, what it leaves untouched, and the fact that broader rescheduling remains unresolved.

General information, not a substitute for the advice of an attorney. Jurisdiction: United States federal law; state law is a separate layer and is not covered here. Information current as of August 2026.

What the April 2026 order actually did

The final order, signed by Acting Attorney General Todd Blanche on 2026-04-23 and published in the Federal Register on 2026-04-28, places two categories of marijuana into Schedule III:

Marijuana contained in a drug product approved by the Food and Drug Administration.
Marijuana subject to a state medical marijuana license.

Both categories are drawn by paperwork rather than by chemistry. Nothing about the plant, the cannabinoid profile or the potency decides whether a given item is inside them — an approval file or a state license does. Two products can be materially identical and sit in different schedules, because the schedule follows the regulatory status of the product, not its contents.

Nothing else moved. The order's reach is fixed by those two conditions (Federal Register, 2026-04-28), so marijuana meeting neither of them remains in Schedule I. That is the sentence that goes missing when the change gets compressed into "marijuana was rescheduled."

The consequence that is already real

One effect landed with the order and is not waiting on anything further: Internal Revenue Code §280E no longer applies to state-licensed medical cannabis businesses (Federal Register, 2026-04-28; Congressional Research Service, LSB11424). That followed automatically from the schedule those businesses now occupy, rather than from any separate tax decision, which is why it needed no second step.

What §280E does, and to which businesses, is set out in the Congressional Research Service briefing linked above. We would rather send a reader to the primary explainer than paraphrase a tax provision into something slightly wrong.

Rescheduling is not legalization, and it is not descheduling

Moving a substance from one schedule to another keeps it inside the Controlled Substances Act (Congressional Research Service, LSB11424). Taking it out of the Act altogether — descheduling — is a different action, and the April order did not take it (Federal Register, 2026-04-28). A page treating Schedule III as the end of federal control over marijuana is describing an outcome that has not been ordered.

This matters more than it sounds. Two categories changed tier inside a statute that still governs them. Everything that follows from being scheduled at all still follows.

Broader rescheduling remains unresolved

The April order is one output of a process that began with an executive order on 2025-12-18 directing the Attorney General to expedite rescheduling to Schedule III (Congressional Research Service, LSB11424). The broader question — whether marijuana generally moves, rather than only the two categories that already did — went to an expedited hearing at the Drug Enforcement Administration, which ran from 2026-06-29 into mid-July 2026.

Broader rescheduling remains unresolved.

This is also the part of the page most likely to age. It is maintained rather than reprinted.

Hemp runs on a different track, and its date is November 12, 2026

These two questions get merged constantly and have nothing to do with each other procedurally. Marijuana's schedule moves through the Controlled Substances Act. Hemp's definition moves through appropriations law — §781 of P.L. 119-37, enacted 2025-11-12 and effective 2026-11-12 (Congressional Research Service, IF13136). Nothing in the April rescheduling order touches it, and nothing in §781 touches marijuana's schedule.

Under §781 of P.L. 119-37 the hemp definition changes in three ways: the delta-9-only measurement is replaced with a total THC standard at 0.3% dry weight, inclusive of THCA and delta-8; finished products are capped at 0.4 mg total THC per container; and cannabinoids not naturally produced by the plant are excluded, along with naturally occurring cannabinoids synthesized outside it.

How much of the market that reaches is contested rather than settled. The U.S. Hemp Roundtable — an industry advocacy group, and the origin of the number repeated everywhere without attribution — estimates that roughly 95% of existing hemp-derived cannabinoid products would fall outside the new definition. It is an estimate from an interested party, and it is worth reading as one.

There is a harder problem underneath the date. §781 of P.L. 119-37 requires the Food and Drug Administration to publish cannabinoid lists and a definition of "container," and that statutory deadline passed in February 2026 without publication (Congressional Research Service, IF13136). The compliance date is fixed; as of August 2026, the definitions needed to comply are still not published.

A partial one-month delay of part of §781 passed the Senate on 2026-08-08 inside a continuing resolution (H.R. 6500, 119th Congress; congress.gov). It is not law — the House had not acted as of August 2026, and the recriminalization of synthetic cannabinoids in §781 of P.L. 119-37 is not covered by the proposed delay in any event. 2026-11-12 remains the operative date. The mechanics, and any movement on them, are tracked on our federal page, because the hemp changes are a separate track entirely.

How to tell a current page from a stale one

Three tells, all checkable in about ten seconds:

Does it name the two categories? A page announcing that marijuana moved to Schedule III without naming the FDA-approved-drug-product category and the state-medical-license category has summarised away the operative limit on the order.
Does it separate rescheduling from descheduling? The two words describe different actions, and only one of them happened in April.
Does it keep hemp and marijuana apart, and does it carry a date? An undated page on an unresolved federal process and a November statutory date is telling you nothing about today.

For how the federal position was arrived at over a much longer run, how American cannabis policy got here covers the century behind it, and what the Farm Bill actually did covers the statute that created the hemp category in the first place.

About this article

This article is general information about the law, published for educational purposes. It is not a substitute for the advice of an attorney. Laws change and vary by state — consult an attorney licensed in your jurisdiction about your specific situation. Jurisdiction covered: United States federal law. Information current as of August 2026.

Sources: the Federal Register rescheduling order published 2026-04-28; the Congressional Research Service legal sidebar on marijuana rescheduling (LSB11424); the Congressional Research Service overview of the federal hemp redefinition (IF13136); and §781 of P.L. 119-37 as enacted 2025-11-12. Where a figure comes from an advocacy organisation rather than a primary source, it is attributed in the sentence that uses it. Published by The FireBar Labs Team.

Common questions

Is marijuana Schedule III now?

Not as a general matter. A final order signed 2026-04-23 and published in the Federal Register on 2026-04-28 placed two categories into Schedule III: marijuana in an FDA-approved drug product, and marijuana subject to a state medical marijuana license. Marijuana outside those two categories remains in Schedule I.

Which two categories moved, exactly?

Marijuana contained in a drug product approved by the Food and Drug Administration, and marijuana subject to a state medical marijuana license (Federal Register, 2026-04-28). Both are defined by regulatory status, so whether an item is covered turns on an approval or a license rather than on what is in it.

Does the April order legalize marijuana federally?

No. Rescheduling relocates a substance within the Controlled Substances Act; descheduling would remove it from that Act, and the April order did not do that (Federal Register, 2026-04-28; Congressional Research Service, LSB11424).

Does any of this change hemp-derived products?

No. Hemp is defined in a different statute and moves on a different clock: §781 of P.L. 119-37, enacted 2025-11-12 and effective 2026-11-12 (Congressional Research Service, IF13136). The April rescheduling order does not alter it, and a page that treats one as evidence about the other is conflating two unrelated tracks.

Why do so many pages report the broader move as finished?

Because the December 2025 executive order asked for exactly that, and the April 2026 order delivered a narrow part of it. Reporting written from the request rather than from the order describes an outcome that has not happened, and it has been repeated widely enough to look like consensus.

What happens next, and when?